Bispecific T-cell engager (BiTE) antibody construct blinatumomab for the treatment of patients with relapsed/refractory non-Hodgkin lymphoma: final results from a phase I study

Goebeler, Maria-Elisabeth; Knop, Stefan; Viardot, Andreas; Kufer, Peter; Topp, Max S.; Einsele, Hermann; Noppeney, Richard; Hess, Georg; Kallert, Stefan; Mackensen, Andreas; Rupertus, Kathrin; Kanz, Lothar; Libicher, Martin; Nagorsen, Dirk; Zugmaier, Gerhard; Klinger, Matthias; Wolf, Andreas; Dorsch, Brigitte; Quednau, Beate D.; Schmidt, Margit; Scheele, Juergen; Baeuerle, Patrick A.; Leo, Eugen; Bargou, Ralf C.

Bispecific T-cell engager (BiTE) antibody construct blinatumomab for the treatment of patients with relapsed/refractory non-Hodgkin lymphoma: final results from a phase I study

Autor(en):

Goebeler, Maria-Elisabeth; Knop, Stefan; Viardot, Andreas; Kufer, Peter; Topp, Max S.; Einsele, Hermann; Noppeney, Richard; Hess, Georg; Kallert, Stefan; Mackensen, Andreas; Rupertus, Kathrin; Kanz, Lothar; Libicher, Martin; Nagorsen, Dirk; Zugmaier, Gerhard; Klinger, Matthias; Wolf, Andreas; Dorsch, Brigitte; Quednau, Beate D.; Schmidt, Margit; Scheele, Juergen; Baeuerle, Patrick A.; Leo, Eugen; Bargou, Ralf C.

Tübinger Autor(en):

Rupertus, Kathrin
Kanz, Lothar

Erschienen in:

Journal of Clinical Oncology (2016), Bd. 34, H. 10, S. 1104-1111

Verlagsangabe:

Amer Soc Clinical Oncology

Sprache:

Englisch

Referenz zum Volltext:

http://dx.doi.org/10.1200/JCO.2014.59.1586

ISSN:

1527-7755